• 1. Evidence of field induced slow magnetic relaxation in cis-[Co(hfac)2(H2O)2] exhibiting tri-axial anisotropy with a negative axial component?
  Denis V. Korchagin,Elena A. Yureva,Alexander V. Akimov,Eugenii Ya. Misochko,Gennady V. Shilov,Artem D. Talantsev,Roman B. Morgunov,Alexander A. Shakin,Sergey M. Aldoshin,Boris S. Tsukerblat Dalton Trans., 2017,46, 7540-7548
• 2. Excimer formation effects and trap-assisted charge recombination loss channels in organic solar cells of perylene diimide dimer acceptors?
  Min Kim,Jae-Joon Lee,Tengling Ye,Panagiotis E. Keivanidis,Kilwon Cho J. Mater. Chem. C, 2020,8, 1686-1696
• 3. Ester-mediated peptide formation promoted by deep eutectic solvents: a facile pathway to proto-peptides?
  Chen-Yu Chien,Sheng-Sheng Yu Chem. Commun., 2020,56, 11949-11952
• 4. Dissolved oxygen sensor based on fluorescence quenching of oxygen-sensitive ruthenium complexes immobilized in sol–gel-derived porous silica coatings
  Analyst, 1996,121, 785-788
• 5. Emerging investigators
  Polym. Chem., 2015,6, 5501-5502

• Solvents and Organic Chemicals Organic Compounds Organic Polymers Polypeptides Polypeptides
• Solvents and Organic Chemicals Organic Compounds Organic Polymers Polypeptides

Comprehensive Overview of Alytesin (8CI,9CI) (CAS No. 31078-12-3): Properties, Applications, and Research Insights

Alytesin (8CI,9CI), identified by its CAS number 31078-12-3, is a bioactive peptide that has garnered significant attention in biochemical and pharmacological research. This compound, derived from the skin secretions of the midwife toad (Alytes obstetricans), belongs to the family of amphibian antimicrobial peptides. Its unique structure and functional properties make it a subject of interest for scientists exploring novel therapeutic agents, particularly in the fields of antimicrobial resistance and immune modulation.

The growing global concern over antibiotic-resistant infections has heightened the demand for alternative antimicrobial agents. Alytesin exhibits potent activity against a broad spectrum of pathogens, including Gram-positive and Gram-negative bacteria, making it a promising candidate for drug development. Researchers are particularly intrigued by its mechanism of action, which involves disrupting microbial cell membranes while demonstrating low cytotoxicity to mammalian cells—a critical feature for clinical applications.

In addition to its antimicrobial properties, Alytesin (8CI,9CI) has shown potential in wound healing and tissue regeneration. Studies suggest that it may stimulate cellular proliferation and modulate inflammatory responses, aligning with current trends in regenerative medicine. These findings have sparked interest in its use for chronic wound management, a pressing healthcare challenge exacerbated by aging populations and rising diabetes rates worldwide.

The structural characteristics of CAS 31078-12-3 contribute to its stability and bioactivity. Its amphipathic α-helical conformation enables effective interaction with biological membranes, while its relatively small molecular weight (approximately 2.5 kDa) facilitates tissue penetration. These attributes are frequently discussed in scientific literature addressing peptide-based therapeutics, a rapidly expanding market projected to reach $50 billion by 2025.

Recent advancements in peptide synthesis technologies have made Alytesin more accessible for research purposes. Solid-phase peptide synthesis (SPPS) and recombinant DNA techniques now allow for cost-effective production of this compound, addressing previous limitations in natural extraction yields. This development is particularly relevant given the increasing focus on sustainable biomolecules in pharmaceutical development.

From a biochemical perspective, Alytesin (8CI,9CI) interacts with various cellular components, including phospholipid bilayers and immune cell receptors. Its ability to modulate cytokine production has implications for treating inflammatory disorders, a research area gaining traction due to the rising prevalence of autoimmune diseases. These properties position the compound as a multifaceted tool for both therapeutic and investigative applications.

The safety profile of CAS 31078-12-3 remains an active area of investigation. Preliminary toxicological studies indicate favorable biocompatibility at therapeutic concentrations, though comprehensive clinical evaluations are still needed. This cautious optimism reflects current industry standards for peptide drug approval processes, where rigorous safety assessments are paramount.

In the context of personalized medicine, Alytesin presents intriguing possibilities. Its modular structure allows for chemical modifications to enhance specific properties, such as stability or target affinity. Researchers are exploring these engineered variants to address individual patient needs, aligning with the growing demand for tailored therapeutic solutions.

The commercial landscape for Alytesin (8CI,9CI) reflects broader trends in biopharmaceutical innovation. While currently primarily used in research settings, its transition to clinical applications would follow the established pathway for peptide drugs—a process receiving increased attention from investors in biotechnology startups. Market analysts note growing patent activity surrounding similar bioactive peptides, signaling commercial potential.

Environmental considerations also factor into discussions about Alytesin. As a naturally occurring compound, its ecological impact differs from synthetic antimicrobials, appealing to advocates of green chemistry in drug development. This aspect resonates with contemporary concerns about pharmaceutical pollution and ecosystem preservation.

Looking ahead, the research trajectory for CAS 31078-12-3 appears promising. Ongoing studies are exploring its potential in combination therapies, where it may enhance the efficacy of conventional antibiotics while reducing required dosages. Such approaches could prove invaluable in combating multidrug-resistant organisms, a critical priority for global health organizations.

For researchers working with Alytesin (8CI,9CI), proper handling and storage are essential to maintain its stability. The peptide should be stored at -20°C in lyophilized form, with reconstitution using appropriate buffers prior to use. These protocols mirror best practices for peptide handling widely discussed in laboratory management forums.

In summary, Alytesin represents a compelling example of nature-inspired drug discovery. Its multifaceted biological activities, combined with advancing production technologies, position it as a compound of significant scientific and potential therapeutic value. As research continues to unravel its full potential, CAS 31078-12-3 may emerge as an important tool in addressing some of contemporary medicine's most pressing challenges.

• 52232-67-4(Teriparatide)
• 320367-13-3(Lixisenatide)
• 12583-68-5(Parathyroid Hormone (1-34), bovine)
• 141758-74-9(exendin-4)
• 16960-16-0(Tetracosactide)
• 106477-83-2(Pancreastatin (swine)(9CI))
• 10466-28-1(a-Melanotropin (swine),13-L-valine-)
• 22006-64-0(ACTH (1-13))
• 141732-76-5(Exenatide acetate)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)